|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________________
FORM
__________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
__________________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________________
|
|
|
|
Not Applicable |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
|
|
|
|
|
(Address of registrant’s principal executive office) |
|
|
|
(Zip code) |
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
|
|
Item 8.01 Other Items.
On September 21, 2021, AbCellera Biologics Inc., (the “Company”), issued a press release announcing that the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesivimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. A copy of the press release is attached herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
|
|
|
|
|
Exhibit |
|
Description |
||||||
99.1 |
|
Press Release issued by AbCellera Biologics Inc. on September 21, 2021. |
||||||
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
Date: September 22, 2021 |
ABCELLERA BIOLOGICS INC. |
||||||||||
|
|
|
|||||||||
|
By: |
|
/s/ Carl L. G. Hansen |
||||||||
|
|
|
Carl L. G. Hansen, Ph.D. |
||||||||
|
|
|
Chief Executive Officer and Director (Principal Executive Officer) |